Critique of phase II agents for non-small cell lung cancer: what is our clinical need and which agents have potential?
At present, a convincing phase II trial in NSCLC is possibly randomized, guided by biomarkers detected by standardized tests, with durable systemic and cerebral activity, inclusion of PROs, and is already in alignment with confirmatory study design and regulatory endpoints.
Authors
- Ilaria Spagnoletti (ORCID: https://orcid.org/0000-0002-5187-2939)
- Alessia Spagnuolo
- Emanuela Nuccio
- Cesare Gridelli
Institutions
- Azienda Ospedaliera S.Giuseppe Moscati (IT)
Publication Details
- Journal
- Expert Opinion on Investigational Drugs
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1080/13543784.2026.2636928
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00